Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$10 Mln
P/E Ratio
--
P/B Ratio
1.69
Industry P/E
81.98
Debt to Equity
0
ROE
-0.73 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-21.12 Mln
EBITDA
$-24.12 Mln
Net Profit
$-27.29 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Biomerica (BMRA)
| 51.15 | -33.80 | -24.64 | -37.18 | -51.99 | -43.43 | -6.62 |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Biomerica (BMRA)
| -75.71 | -62.69 | -13.88 | -21.89 | 64.68 | 77.88 | -54.35 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.58 | 10,289.47 | 14.38 | 12.69 | |
| 73.36 | 9,544.04 | 92.52 | 2.52 | |
| 162.93 | 8,064.21 | -- | -25.23 | |
| 293.06 | 10,728.90 | 773.26 | 1.2 |
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's... diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops, markets, and sells COVID-19 diagnostic tests to indicate if a person has been infected by COVID-19. The company was incorporated in 1971 and is headquartered in Irvine, California. Address: 17571 Von Karman Avenue, Irvine, CA, United States, 92614 Read more
Chief Executive Officer
Mr. Zackary S. Irani
Chief Executive Officer
Mr. Zackary S. Irani
Headquarters
Irvine, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Biomerica Inc (BMRA) stood at $ 9 Mln as on 30-Nov-24
The share price of Biomerica Inc (BMRA) is $3.63 (NASDAQ) as of 24-Apr-2025 12:34 EDT. Biomerica Inc (BMRA) has given a return of -51.99% in the last 3 years.
Biomerica Inc (BMRA) has a market capitalisation of $ 10 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Biomerica Inc (BMRA) is 1.69 times as on 22-Apr-2025, a 48% discount to its peers’ median range of 3.26 times.
Since, TTM earnings of Biomerica Inc (BMRA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Biomerica Inc (BMRA) and enter the required number of quantities and click on buy to purchase the shares of Biomerica Inc (BMRA).
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops, markets, and sells COVID-19 diagnostic tests to indicate if a person has been infected by COVID-19. The company was incorporated in 1971 and is headquartered in Irvine, California. Address: 17571 Von Karman Avenue, Irvine, CA, United States, 92614
The CEO & director of Mr. Zackary S. Irani. is Biomerica Inc (BMRA), and CFO & Sr. VP is Mr. Zackary S. Irani.
There is no promoter pledging in Biomerica Inc (BMRA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,070
|
|
|
1,049
|
|
|
978
|
|
|
820
|
| Biomerica Inc. (BMRA) | Ratios |
|---|---|
|
Return on equity(%)
|
-95.77
|
|
Operating margin(%)
|
-85.76
|
|
Net Margin(%)
|
-100.52
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Biomerica Inc (BMRA) was $0 Mln.
$-0.03
(
